Open an Account
search icon
3
NOTIFICATIONS
Best Algo trading app in India
Bigul

BAFNA PHARMACEUTICALS LTD. - 532989 - Announcement under Regulation 30 (LODR)-Meeting Updates

 We would like to inform you that the 24th Annual General Meeting of the Members of Bafna Pharmaceuticals Limited is scheduled to be held on Thursday, the 27th day of June 2019, at 03.00 PM, at # Andhra Social and Cultural Association, Krishna Hall, No.22, Vijayaraghava Road, T. Nagar, Chennai - 600 017. Please find attached the notice of Annual General Meeting. The said notice is also displayed on the website of the Company www.bafnapharma.com
06-06-2019
Bigul

BAFNA PHARMACEUTICALS LTD. - 532989 - Reg. 34 (1) Annual Report

 Annual Report for the year ending 31st March 2019.
06-06-2019
Bigul

Bafna Pharmaceuticals Ltd - 532989 - Reg.24(A)-Annual Secretarial Compliance

 Annual Secretarial Compliance Report Sr. No. Particulars Details 1Period for which the report has been issued 31/03/2019 2Date of Report30/05/2019 3 Name of the Certifying Firm A.K.JAIN & ASSOCIATES 4 Name of the Certifying Individual BALU SRIDHAR 5Membership TypeFCS 6 Membership Number 5869 7 CP No. 3550 8 Whether any observations/qualification reported by the Secretarial Auditor ? Yes
30-05-2019
Bigul

Annual report for Bafna Pharmaceuticals Ltd. for FY-2019
28-05-2019
Bigul

BAFNA PHARMACEUTICALS LTD. - 532989 - Outcome of Board Meeting

 The Board of Directors of the Company at their meeting held on today inter-alia transacted the following business.:- AUDITED FINANCIAL RESULT 1. Approval of audited financial results of the Company for the quarter and year ending 31st March 2019 (standalone and Consolidated). M/s. R. Sathyanarayanan & Co, the Statutory Auditors of the Company have issued Audit Report with modified opinion along with Statement on impact of Modified opinion thereon. Please find enclosed 'Audited Financial Results, Audit Report, 'Statement of Assets & Liabilities' and Statement on Impact of Modified Opinion thereon.the year ended on March 31, 2019. ANNUAL GENERAL MEETING The 24th Annual General Meeting of the members of the Company is scheduled to be held on 27th June 2019 CLOSURE OF REGISTER OF MEMBERS The Register of members will be closed from 24th June 2019 to 27th June 2019 (both days inclusive) The Board Meeting commenced at 15.30 Hours and concluded at 19.00 Hours.
27-05-2019
Bigul

BAFNA PHARMACEUTICALS LTD. - 532989 - Board Meeting Intimation for Results And Others

 BAFNA PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/05/2019 ,inter alia, to consider and approve Notice is hereby given that a meeting of the Board of Directors of the Company will be held on Monday, 27th May 2019 at the registered office of the Company, to inter alia consider and adopt audited financial results for the quarter / year ended 31st March 2019 and any other business with the permission of the Chair. Further in accordance with the Code of Conduct for prevention of Insider Trading pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 2015 the trading window for dealing in securities of the Company shall remain closed until 48 hours after the financial results approved at the meeting are made public.
20-05-2019
Bigul

Bafna Pharmaceuticals Ltd - 532989 - Sub: Certificate From Practicing Company Secretary For The Half Year Ended 31St March 2019 Ref: Regulation 40(9) Of The SEBI (LODR) Regulations, 2015

 Certificate from Practicing Company Secretary under Regulation 40(9) of SEBI (LODR) Regulations, 2015 for the half year ended 31st March 2019 is hereby enclosed for your reference. Request you to take the same on record.
09-05-2019
Bigul

Bafna Pharmaceuticals Ltd - 532989 - Format of Initial Disclosure to be made by an entity identified as a Large Corporate

 Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompayBAFNA PHARMACEUTICALS LTD. 2CININE878I01014 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 21 4Highest Credit Rating during the previous FY D 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)CRISIL LTD. 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkBSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: JITENDRA KUMAR PAL Designation: COMPANY SECRETARY EmailId: [email protected] Name of the Chief Financial Officer: MELAGIRI SRIDHAR Designation: CFO EmailId: [email protected] Date: 30/04/2019 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.
30-04-2019
Bigul

Bafna Pharmaceuticals Ltd - 532989 - Shareholding for the Period Ended March 31, 2019

 Bafna Pharmaceuticals Ltd has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2019. For more details, kindly Click here
16-04-2019
Bigul

BAFNA PHARMACEUTICALS LTD. - 532989 - Statement Of Investor Complaints For The Quarter Ended March 2019

 No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- JITENDRA KUMAR PALDesignation :- Company Secretary and Compliance Officer
16-04-2019
Next Page
Close

Let's Open Free Demat Account